A tiny ingestible sensor can measure temperature from inside the body

A tiny ingestible sensor can measure temperature from inside the body
After being swallowed, the devices could offer continuous monitoring of patients who are sick or at risk of hypothermia.
Watch Video
Anne Trafton | MIT News
Publication Date: June 15, 2026
In a hospital or at home, temperatures are usually taken using an oral or forehead thermometer, but these do not always accurately reflect the core body temperature. Measuring core temperature from within the body could make it easier to determine whether someone is sick, and whether they’re at risk of spiking a dangerous fever.

To make it more feasible to obtain core body temperature measurements, MIT engineers have developed an ingestible sensor that can send continuous temperature updates from the GI tract.

The sensor is shaped like a tiny blueberry, 6 millimeters in diameter and 4 millimeters in height. That makes it much smaller than existing ingestible temperature sensors, which are more difficult to swallow and pose a potential risk of obstructing the GI tract.

“A sensor like this gives us the ability to monitor infections and identify them early,” says Giovanni Traverso, an associate professor of mechanical engineering at MIT, a gastroenterologist at Brigham and Women’s Hospital, and an associate member of the Broad Institute of MIT and Harvard. “That’s very relevant, particularly for at-risk populations like people who are immunosuppressed from chemotherapy treatments or immunosuppressive drugs.”

Video thumbnail Play video

Ingestible sensors could also enable more accurate temperature measurements for fertility tracking, and for monitoring people during anesthesia.

Traverso and Anantha Chandrakasan, MIT’s provost and the Vannevar Bush Professor of Electrical Engineering and Computer Science, are the senior authors of the new study. MIT postdoc Saransh Sharma is the lead author of the paper, which appears today in Nature Electronics.

Ingestible electronics

A handful of ingestible temperature sensors have become commercially available in recent years, but most are the size of a multivitamin or slightly larger, making them more challenging to swallow. Their size can also increase the risk of obstructing the GI tract.

Those capsules tend to be large due to the complex circuits they include, which require a great deal of power. That power is provided by relatively large, on-board batteries that make up much of the bulk of the capsule.

The MIT team wanted to design sensors that could measure temperature accurately, but at a much smaller size.

“The reason for them to be small is safety,” Traverso says. “We want something that is so small that the risk of any blockage or obstruction is highly mitigated, and also so that it can be easily ingested.”

To create a smaller device, the researchers set out to reduce the size of all of the main components — the temperature-sensing circuit, the antenna that relays temperature data, and the battery.

For the circuit, they created their own customized circuit that can fit onto a 1-square-millimeter silicon chip. To reduce the chip’s power consumption, the researchers designed an oscillator based on leakage current — the small current that flows through a circuit when it’s off. The frequency of this current varies depending on the temperature of the chip’s surroundings.

This circuit, which can detect temperature with an accuracy of 0.01 degrees Celsius, requires very little power — about 10 nanowatts. This means that it can be powered with a 1.55-volt coin cell battery, which is 4.8 millimeters in diameter and about 1.6 millimeter thick.

The new design further cuts energy consumption by using a communication strategy known as backscattering. This approach allows most of the power requirements to be outsourced to an external antenna that is located outside the body, within a foot or two of the sensor. The external antenna emits an ultra-high-frequency radio wave, which is then modulated by a tiny antenna within the sensor and sent back to the external antenna. By interpreting the changes in the radio wave, the external antenna can calculate the temperature value.

“We combined all of these different pieces together — the silicon chip, the battery, and the antenna — and we made it into an ingestible capsule, which is the smallest ingestible capsule that we have seen for temperature-sensing paradigms,” Sharma says.

The internal antenna sends out a temperature reading once every second, allowing for continuous monitoring of temperature.

Tiny thermometers

The researchers envision that this kind of sensor could be useful in several scenarios, including monitoring infection and observing patients during and after anesthesia. Anesthesia often disrupts the body’s normal temperature regulation mechanisms, which can put patients at risk of hypothermia.

This type of device could also be used at home, for monitoring fevers in children, or measuring core body temperature as a marker of ovulation, for fertility purposes. It could also be useful for monitoring athletes, soldiers, or anyone else who might be exposed to extreme temperatures.

To explore these possible uses, the researchers tested the sensors in animals while they were under anesthesia, and found that they could accurately detect and transmit temperature information. They also obtained accurate readings from animals that were awake and actively moving.

The researchers are now working on combining the temperature sensor with other sensors that could measure vital signs such as heart rate. They hope to begin testing these types of sensors in clinical trials within the next few years.

If proven effective for people in high-risk situations, Traverso believes such sensors could become widely used by anyone who needs to monitor their temperature.

“I think this could replace all thermometers, because it’s the most accurate way of taking temperature,” he says. “If we have miniature systems that can be easily swallowed and give very accurate data that’s superior to the current data, I think it can be helpful in so many ways.”

Other authors of the paper include Yubin Cai, Injoo Moon, Zhenming Yang, Peter Chai, Niora Fabian, Kailyn Schmidt, Alison Hayward, Andrew Pettinari, Maria Platero, Benedict Laidlaw, and Ashley Guevara.

The research was funded by the 711th Human Performance Wing, the Defense Advanced Research Projects Agency (DARPA), and the Advanced Research Projects Agency for Health (ARPA-H), which notes that the views and conclusions contained in this article are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the United States government.

A breakthrough in electron microscopy delivers sharper images of our body’s tiniest proteins

A breakthrough in electron microscopy delivers sharper images of our body’s tiniest proteins

UC Berkeley physicists have introduced phase contrast to the electron microscope, allowing scientists to see much smaller molecules and smaller structures inside cells.

By Robert Sanders

two purple and pink beams converging on metal apparatus, with blue and red molecules sprinkled throughout background
A laser (purple) is powerfully amplified by highly polished mirrors and focused on the electron beam (blue) to shift its phase and increase the cryo-EM microscope’s contrast, allowing biologists to image smaller proteins and the crowded structures inside cells.
SayoStudio
June 11, 2026

Nearly 100 years ago, a seemingly simple discovery revolutionized the microscope. The introduction of phase-contrast, which garnered a Nobel Prize in 1953, brought into clear view structures inside cells that had previously been too faint or washed out for biologists to study.

UC Berkeley physicists have now adapted the phase contrast technique to the electron microscope, which has about 10,000 times the magnification of microscopes using optical light.

The addition of a so-called laser phase plate has the potential to greatly improve cryoelectron microscopy (cryo-EM), a technique for determining the structure of molecules that itself revolutionized the understanding of proteins and accelerated new drug discovery starting a decade ago. Despite its impact, however, cryo-EM still struggles to produce clear images of small molecules — including most human proteins. A laser phase plate promises clear images of most proteins in the cell down to one-third the size of those that are a challenge for today’s machines.

The addition of a laser phase plate seems certain to revolutionize a newer technique referred to as cryoelectron tomography (cryo-ET), which assembles a number of different angular views of a molecule or protein into a 3D image. This makes it possible to analyze proteins in their natural environment — inside cells — instead of in isolation in a solution.

two black and white images of different contrast
Cryo-EM images of the blood protein hemoglobin, showing the much-improved contrast achieved with a laser phase plate. The images, which show many hemoglobin molecules, are analyzed to assemble a detailed 3D structure of the protein.
Holger Müller, Jessie Zhang/UC Berkeley
“Cryo-EM has become the new, fastest-growing method for resolving the structure of biological macromolecules, and cryo-ET is expected to show how these molecules work together in their natural, cellular context,” said Holger Müller, a UC Berkeley professor of physics and faculty scientist at Lawrence Berkeley National Laboratory who led the development effort. “But because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”

Crucial to the development is the world’s most intense, focused continuous-wave laser, which interacts with the electron beam to change its phase. This phase change boosts contrast for small molecules, such as hemoglobin, and for molecules and structures inside cells, such as the nucleus and mitochondria.

“With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, founding technical director of imaging at Biohub in Redwood City, California “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”

Biohub provided funding to Müller to purchase a state-of-the-art cryo-EM machine that he then outfitted with a laser phase plate, creating a microscope he calls Theia, named after the ancient Greek Titaness of light and radiance. Carragher is overseeing the development of a similar instrument at Biohub’s imaging lab in Redwood City — this one featuring a dual-laser system, based on theoretical work by Müller and his colleagues. In this system, the two perpendicular laser beams operate at about half power, making the components less likely to burn out and reducing aberrations.

Both groups are collaborating with the firm Thermo Fisher Scientific, the primary manufacturer of cryo-EM machines.

Holger Müller explains how a laser phase plate works and how it improves the contrast of cryoelectron microscope (cryo-EM) images. (Video credit: Biohub)
“Theia is the Formula 1 microscope,” Müller said. “It has extra electron optics that give it better resolution than the standard cryo-EM, even without the laser. With the addition of the laser phase plate, we hope that it really becomes the world’s best instrument overall.”

Müller and his Berkeley team published their newest images and details of the cryo-EM’s laser phase plate today (June 11) in the journal Science. Biohub’s two-laser system is described in an online preprint.

Biological imaging

Animal and plant cells are mostly water and thus transparent in a light microscope, which should make it easy to see structures such as the nucleus and mitochondria inside. But these structures are small and scatter only a small amount of light, which makes them only slightly darker than the rest of the cell’s insides. This low contrast has typically been improved by staining the cell, though staining also kills the cell.

a man in dark glasses standing in front of a tall complex apparatus
Holger Müller standing in front of the Thermo Scientific Krios cryo-EM outfitted with a novel laser phase plate to dramatically improve the microscope’s contrast and ability to image smaller molecules and smaller structures inside cells.
Robert Sanders/UC Berkeley
In 1930, Dutch scientist Frits Zernike realized that the brightness or amplitude of the light was not the only feature affected when passing through a cell. The scattered light is also slowed down in a biological sample, which shifts its phase — the timing of the peak of the waveform — by a small amount. While this phase shift is invisible to the human eye, it can be turned into visible contrast by also phase shifting the non-scattered light by 90 degrees. When the scattered and non-scattered light are ultimately focused on the retina, features in the sample are enhanced relative to the background, boosting the contrast. Zernike received the 1953 Nobel Prize in Physics for this discovery.

By the early 1940s, the phase-contrast microscope had proved its value and scientists speculated about adapting this technique to increase contrast in the electron microscope, which uses a beam of electrons to image much smaller structures, such as proteins. But attempts to make a phase plate that shifts the phase of an electron beam reduced the beam intensity too much, made the images unstable, or resulted in lower resolution.

In 2010, Müller and Robert Glaeser, now a Berkeley professor emeritus of molecular and cell biology, wrote a paper proposing a way to create the phase shift by using an intense laser, which would not dim the electron beam.

Glaeser is a pioneer of cryo-EM, a major improvement in electron microscopy and theoretically a simpler method for determining molecular structures than X-ray crystallography, which requires that a molecule actually forms a crystal and that the researcher has access to a bright source of X-rays. But a major problem with electron microscopy is that the electron beam heats up and eventually damages its target, limiting image detail. Coating the specimen with metal to prevent this and enhance the contrast only makes fuzzier images.

In the 1960s, scientists proposed freezing samples to slow down sample destruction. Glaeser demonstrated that freezing samples reduced radiation damage and proposed reducing damage even further by lowering the power of the electron beam while irradiating thousands of frozen molecules simultaneously. Though each molecule in the sample would be in a random orientation, computers could combine all the images to create a highly detailed structure.

The originators of cryo-EM were awarded a Nobel Prize in Chemistry in 2017, and in their acceptance remarks credited Glaeser’s work. According to the Nobel Committee, cryo-EM “both simplifies and improves the imaging of biomolecules. This method has moved biochemistry into a new era.”

After the publication of the 2010 paper, Müller spent 15 years realizing the goal of a laser phase plate for cryo-EM, funded in part by a grant from the National Institutes of Health. First, he and his team had to develop a way to focus a continuous laser onto a small spot to create light intense enough to shift the phase of an electron beam by 90 degrees. After 10 years, they achieved this by trapping the laser beam in a spherical, mirrored cavity that both focuses the beam and intensifies it as the light bounces back and forth more than 10,000 times. The entire optical cavity housing the laser phase plate is less than four inches wide, tucked inside a microscope that stand 14 feet tall.

“It’s 75 kilowatts focused to a few microns,” Müller said. “That’s more powerful than what you use for welding. It’s more power than a military laser. It builds up the brightest continuous laser focus ever.”

two black and white images of different contrast
Cryo-EM images of the iron storage protein apoferritin, without and with a laser phase plate. The images, which are of many apoferritin molecules, are analyzed to produce a detailed 3D structure of the protein.
Holger Müller, Jessie Zhang/UC Berkeley
They proved that the concept worked by installing a laser phase plate in one of Glaeser’s old microscopes, but Biohub funding later allowed them to purchase a customized, state-of-the-art Thermo Scientific Krios cryo-EM and refit it. In the new paper, they demonstrate that the powerful focused laser beam produces higher resolution images for six different samples of different sizes and different sample preparation.

“For the most challenging cases — small particles, bad specimens — the laser produces a very considerable advantage,” Müller said.

In their paper, they show reconstructed images of a protein from muscle called aldolase, which is relatively easy to image with today’s cryo-EM machines, and for hemoglobin — a protein that carries oxygen in blood — which is at the lower limit for current machines. The laser phase plate improved the resolution of the protein structure in both cases, but more so for the smaller molecule, hemoglobin.

“The bottom line is, if you have a large protein and a really good sample — a fresh one or one frozen without bubbles, for example — you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Müller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”

a man working with a large chrome apparatus
A Thermo Scientific Krios cryoelectron microscope that Biohub has outfitted with two powerful lasers to improve image contrast.
Biohub
Protein size is measured in daltons — named after English chemist John Dalton and equivalent to 1/12 the mass of a carbon-12 atom — and cryo-EM today can barely image proteins smaller than 70 kilodaltons, which make up about 90% of the human proteome. With the laser phase plate, it’s now possible — though difficult — to image down to 50 kilodaltons (even smaller than hemoglobin).

Soon, Müller hopes, this will be improved to 17 kilodaltons (the size of the protein myoglobin). He is optimistic that that can be achieved with a focused electron beam, as opposed to a defocused beam, which without the laser phase plate is now required to get any contrast at all. This advantage would be another benefit of the laser phase plate and would deliver another factor-of-two boost in contrast and signal-to-noise ratio, on top of the one already achieved. A laser phase plate should be able to extract contrast from phase changes in the focused electron beam alone, he said.

“This technology is a step function change for biology,” said Stephani Otte, Biohub’s Vice President of Imaging Science. “We are going to be able to see how molecular machines operate inside the living cell, in context, for the first time. What was once invisible will become visible — and that changes everything about how we understand disease.”

Müller’s co-authors are Glaeser, UC Berkeley postdoctoral fellows and co-first authors Petar Petrov and Jessie Zhang; staff scientist Jonathan Remis, postdoctoral fellow Hang Cheng; and current and former physics graduate students Jeremy Axelrod, Eric Cooper, Ian Hicklin, Shahar Sandhaus and Cooper Schnurr.

Carragher and David Agard, founding scientific director of imaging at Biohub, are co-leads of Biohub’s Dynamic Structural Cell Biology group and co-corresponding authors of the Biohub preprint, along with Biohub engineer Pavel Olshin.

Related Information
Laser phase plate improves structure determination of small proteins by cryo-EM (Science)
Biohub press release
Design of an electron microscope phase plate using a focused continuous-wave laser (New Journal of Physics, 2010)
Crossed laser phase plates for transmission electron microscopy (Nature Communications)
Biohub’s dual laser phase plate preprint
Holger Müller’s laboratory website
Biohub

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)
NEWS PROVIDED BY
Eli Lilly and Company
Jun 06, 2026, 14:30 ET
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity

In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%)

In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1C

INDIANAPOLIS, June 6, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes – common obesity-related conditions.1,2 The findings from TRIUMPH-1 and TRANSCEND-T2D-1 were presented at the American Diabetes Association (ADA) 86th Scientific Sessions, with TRANSCEND-T2D-1 results simultaneously published in The Lancet.

“Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos,” said Ania Jastreboff, M.D., Ph.D., Professor of Medicine & Pediatrics (Endocrinology) at the Yale School of Medicine, Director of the Yale Obesity Research Center (Y-Weight), and lead investigator. “In TRIUMPH-1 and TRANSCEND-T2D-1, treatment with retatrutide resulted in substantial weight reduction together with clinically meaningful improvements in glycemia, knee osteoarthritis pain, and obstructive sleep apnea, with many individuals reaching what are classified as healthy-range weight and normal blood sugar levels. These findings demonstrate what may be possible when we treat obesity and impact overall health, and what this could mean for people living with obesity and its related complications.”

TRIUMPH-1 included an overarching trial for adults with obesity and two nested basket trials: one for knee osteoarthritis pain and one for moderate-to-severe obstructive sleep apnea. Retatrutide met the primary endpoints in each trial at 80 weeks, delivering powerful weight loss along with significant improvements in knee osteoarthritis pain and obstructive sleep apnea. Participants on retatrutide 9 mg and 12 mg lost an average of 64.4 lbs (25.9%) and 70.3 lbs (28.3%), respectively, while those on the 4 mg dose, reached with a single dose escalation step, lost an average of 47.2 lbs (19.0%).3 Notably, 65.3% of participants on retatrutide 12 mg achieved a BMI <30, and 33.3% reached a BMI <25, representing healthy BMI. In a pre-specified extension for participants with baseline BMI ≥35, those continuing on retatrutide 12 mg through 104 weeks lost an average of 85.0 lbs (30.3%). In addition to improving weight measures, retatrutide reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores by up to 4.3 points (73.1%) from a baseline of 6.0 in participants with knee osteoarthritis and apnea-hypopnea index (AHI) by up to 36.1 events per hour (60.6%) from a baseline of 58.6 events per hour in participants with moderate-to-severe obstructive sleep apnea.4